Medical Xpress July 13, 2024
Andreas Birkenfeld, The Conversation

Obesity increases the risk of developing a number of cancers, so it stands to reason that drugs that reduce body weight should also reduce the risk of developing these cancers.

Researchers in the US wanted to know if weight-loss drugs known as GLP-1 agonists reduced the risk of people getting any of the 13 cancers associated with obesity. Their results were recently published in JAMA Network Open.

GLP-1 is a hormone produced by your gut after eating a meal that signals you are full. GLP-1 drugs deliver synthetic GLP-1, which is much longer lasting than the GLP-1 produced by the body. Recent versions of these drugs include Ozempic (used to treat type 2 ) and Wegovy (used for weight loss)....

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Provider, Survey / Study, Trends
New 'how-to guide' for future rapid vaccine development
Infographic: R&D Spending Growth of Top Pharma Companies
Medicare prescription drug pricing variance: 5 things to know
Payer group 'deeply concerned' by Medicare weight loss drug coverage proposal
Adoption Of Model-Informed Drug Development Can Improve Pharma ROI

Share This Article